ν΄λ‘νμ§λ―Ό
ν΄λ‘νμ§λ―Όμ μ§μ©μ±μ΄ λ§€μ° λμ νλμ§ μΌλ£ νλ§μ΄μ½λ°ν 리μ νμμ μ λλ€. μμνμμλ μ£Όλ‘ κ³ μμ΄ λλ³, κ° λλ³μ± μ‘μμ’ κ³Ό κ°μ λλ³ μ μ¬ μ¦νκ΅° λ° *λ§μ΄μ½λ°ν 리μ μλΉμ* 볡ν©μ²΄(MAC) κ°μΌ μΉλ£λ₯Ό μν λ€μ λ³μ© μλ²μ μΌλΆλ‘ μ¬μ©λ©λλ€. **μμ μμ :** * **λ³μ© μλ²:** λ§μ΄μ½λ°ν 리μλ λ°λ©Έμ΄ λ§€μ° μ΄λ ΅κ³ λ΄μ±μ΄ μκΈ°κΈ° μ¬μ°λ―λ‘ ν΄λ‘νμ§λ―Όμ κ±°μ λ¨λ μλ²μΌλ‘ μ¬μ©λμ§ μμ΅λλ€. * **μ§μ©μ±:** κ·Ήλμ μ§μ©μ±μΌλ‘ μΈν΄ μ§λ°© μ‘°μ§κ³Ό λ§μλ΄νΌκ³(λμμΈν¬)μ λλμΌλ‘ μΆμ λ©λλ€. * **μ°©μ:** μΌλ£λ‘μμ νΉμ±μΌλ‘ μΈν΄ νΌλΆ, λ, 체μ‘μ΄ λμ λκ³ μ€λ μ§μλλ λ³μμ μΌμΌν€λ νΉμ§μ μΈ λΆμμ©μ΄ μμ΅λλ€. * **ν보μ μ΄λ €μ:** μμμ¬κ° μλλ¬Όμ μν΄ μ νν μ©λμ ꡬνκ³ μ‘°μ νλ κ²μ΄ λ§€μ° μ΄λ €μΈ μ μμΌλ©°, μ’ μ’ μ‘°μ μ½μ¬μ λμμ΄ νμν©λλ€.
μμ© κΈ°μ : Clofazimine exerts a slowly bactericidal effect against susceptible mycobacteria (*M. leprae*, *M. tuberculosis*, *M. avium* complex, *M. bovis*, *M. chelonei*). * **DNA Binding:** It binds directly to mycobacterial DNA (preferentially at guanine base sequences) β blocks template function β **inhibits DNA replication and cell growth**. * **Intracellular Accumulation:** It is heavily taken up by macrophages, concentrating the drug exactly where intracellular mycobacteria reside. * **Immunomodulation:** Exhibits anti-inflammatory and immunosuppressive properties, likely by inhibiting T-lymphocyte activation and proliferation, though the exact mechanism remains poorly understood.
λλ¬Ό μ’ λ³ μ©λ
- Avian mycobacteriosis Β· 6 mg/kg PO once daily Β· PO Β· q24h Β· Protocol 1: with rifampin 45 mg/kg and ethambutol 30 mg/kg.
- Avian mycobacteriosis (recommended regime for raptors) Β· 1.5 mg/kg PO q24h Β· PO Β· q24h Β· Protocol 2: with ethambutol 20 mg/kg, cycloserine 5 mg/kg, enrofloxacin 15 mg/kg q12h.
- Mycobacterium avium complex (MAC) as part of a multi-drug regimen Β· 4 mg/kg PO once daily Β· PO Β· q24h Β· Other drugs that may be used in combination include doxycycline, clarithromycin, and/or enrofloxacin.
- M. avium intracellularae complex infections, leprosy, or opportunistic mycobacteriosis Β· 4-8 mg/kg PO once a day Β· PO Β· q24h Β· 4 weeks Β· Usually as part of a multi-drug protocol.
- Mycobacterial infections Β· 4-8 mg/kg Β· PO Β· q24h Β· 2-6 months Β· Generally used in combination therapy with other antimicrobials including fluoroquinolones and clarithromycin.
- Treatment of feline leprosy Β· 25-50 mg once per day or 50 mg every other day Β· PO Β· q24h or q48h Β· Using a regimen of either two or three drugs (with clarithromycin and/or rifampin).
- Treatment of localized atypical mycobacterial infections Β· 8 mg/kg PO once daily Β· PO Β· q24h Β· At least 4 weeks beyond complete clinical resolution Β· Perform wide surgical excision of lesion if possible. Base antibiotic selection on culture and susceptibility results.
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Use with caution in patients with pre-existing gastrointestinal conditions (diarrhea, abdominal pain)
- Known hypersensitivity to clofazimine
μ΄μλ°μ
- Skin, eye, and body fluid discoloration (pink to brownish-black)
- Gastrointestinal pain, nausea, vomiting, diarrhea (dose-limiting)
- Hepatotoxicity (reported in a dog receiving concurrent rifampin)
- Photosensitization (reported in a cat)
- Nausea
- Diarrhoea
- Discoloration of skin, eyes, and body fluids (red-brown/orange)
- Renal impairment
- Hepatic impairment
- Photosensitization
μ½λ¬Ό μνΈμμ©
- Isoniazid Β· May reduce clofazimine levels in the skin and increase amounts in plasma and urine; clinical significance is unclear.
- Dapsone Β· May reduce the anti-inflammatory effects of clofazimine; clinical significance is unclear.
λͺ¨λν°λ§
- Efficacy against mycobacterial disease
- Adverse effects (primarily gastrointestinal)
- Hepatic function (especially in dogs)
- Hepatic function (ALT, AST, ALP, Bilirubin)
- Renal function (BUN, Creatinine, SDMA)
- Clinical signs of photosensitization
- Gastrointestinal tolerance
κ³Όμ©λ
Very limited data is available. The LD50 for rabbits is 3.3 g/kg and is greater than 5 g/kg in mice, rats, and guinea pigs. Treatment, if required, would include gut emptying and supportive care. Contact an animal poison control center for additional guidance.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.